X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
CardiolRx™ (cannabidiol), is a oral solution formulation being developed for use in heart diseases. Cannabidiol inhibits activation of the inflammasome pathway, an intracellular process known to play an important role in the inflammation and fibrosis associated disorders.
Lead Product(s): Cannabidiol
Therapeutic Area: Cardiology/Vascular Diseases Product Name: CardiolRx
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 17, 2023
Details:
CardiolRx (cannabidiol), is a pharmaceutically produced oral solution formulation that is being clinically developed for use in heart diseases and inhibits activation of the inflammasome pathway.
Lead Product(s): Cannabidiol
Therapeutic Area: Cardiology/Vascular Diseases Product Name: CardiolRx
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 12, 2022
Details:
CardiolRx (cannabidiol), is a pharmaceutically produced oral solution formulation that is being clinically developed for use in heart diseases and inhibits activation of the inflammasome pathway.
Lead Product(s): Cannabidiol
Therapeutic Area: Cardiology/Vascular Diseases Product Name: CardiolRx
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 07, 2022
Details:
Study results demonstrate the active pharmaceutical ingredient ("API") in CardiolRx™ (Cannabidiol) inhibits and also promotes the reversal of mechanisms known to play a role in the occurrence and development of fibrotic CVD.
Lead Product(s): Cannabidiol
Therapeutic Area: Cardiology/Vascular Diseases Product Name: CardiolRx
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 03, 2022
Details:
CardiolRx (cannabidiol), is a pharmaceutically produced oral solution formulation that is being clinically developed for use in heart diseases and inhibits activation of the inflammasome pathway.
Lead Product(s): Cannabidiol
Therapeutic Area: Cardiology/Vascular Diseases Product Name: CardiolRx
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 03, 2022
Details:
CardiolRx (cannabidiol), is a pharmaceutically manufactured oral solution formulation that is being clinically developed for use in Recurrent Pericarditis and inhibits activation of the inflammasome pathway.
Lead Product(s): Cannabidiol
Therapeutic Area: Cardiology/Vascular Diseases Product Name: CardiolRx
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 17, 2022
Details:
CardiolRx (cannabidiol), is a pharmaceutically manufactured oral solution formulation that is being clinically developed for use in Acute Myocarditis and inhibits activation of the inflammasome pathway.
Lead Product(s): Cannabidiol
Therapeutic Area: Cardiology/Vascular Diseases Product Name: CardiolRx
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 25, 2021
Details:
The LANCER trial is designed to evaluate the efficacy and safety of CardiolRx as a cardioprotective therapy to reduce mortality and major cardiovascular events in patients hospitalized with COVID-19.
Lead Product(s): Cannabidiol
Therapeutic Area: Infections and Infectious Diseases Product Name: CardiolRx
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 18, 2021
Details:
CardiolRx (cannabidiol), is a pharmaceutically manufactured oral solution formulation that is being clinically developed for use in Acute Myocarditis and inhibits activation of the inflammasome pathway.
Lead Product(s): Cannabidiol
Therapeutic Area: Cardiology/Vascular Diseases Product Name: CardiolRx
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 24, 2021
Details:
Topline results demonstrated that CardiolRx was safe and generally well tolerated at all dose levels, with no serious adverse events reported in the study.
Lead Product(s): Cannabidiol
Therapeutic Area: Cardiology/Vascular Diseases Product Name: CardiolRx
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 12, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
